DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT. A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https:/ ...

Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the BoardMr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total RevenueBoard Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive ...

Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United StatesFor U.S. media and investors onlyDUBLIN, Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A treatment ...

DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera® (zanidatamab-hrii), the first chemotherapy-free dual HER2-targeted bispecific antibody indicated for biliary tract cancer (BTC). Ziihera was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on N ...

Core Insights - Jazz Pharmaceuticals is showcasing its advancements in oncology research at two major conferences: the 2024 San Antonio Breast Cancer Symposium (SABCS) and the 66th Annual American Society of Hematology (ASH) Annual Meeting [1][3] - The company will present significant data on its drug Ziihera® (zanidatamab-hrii), which has recently received FDA approval for treating HER2-positive biliary tract cancer [3][10] - Jazz is committed to improving treatment outcomes for patients with challenging HER2-positive cancers through ongoing clinical trials [3][9] SABCS Presentations - Jazz will present a trial-in-progress poster for the Phase 3 EmpowHER303 trial, comparing zanidatamab with trastuzumab in patients with metastatic HER2-positive breast cancer [2] - A spotlight presentation will feature new data from a Phase 1b/2 study of zanidatamab combined with evorpacept in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer [2] ASH Presentations - At ASH 2024, Jazz will highlight 13 abstracts focusing on oncology research, emphasizing its dedication to enhancing standards of care in blood cancers and hematologic diseases [3] - Key presentations will include a randomized comparison of Vyxeos® (daunorubicin and cytarabine) in high-risk acute myeloid leukemia patients [4][25] Ziihera® Overview - Ziihera is a bispecific HER2-directed antibody that targets two extracellular sites on HER2, leading to tumor growth inhibition and cell death [8] - The drug is indicated for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer, with FDA approval based on overall response rates [8][10] Development and Designations - Ziihera has received Breakthrough Therapy designation for HER2 gene-amplified biliary tract cancer and Fast Track designations for other indications [10] - The drug is being developed in collaboration with BeiGene, under license from Zymeworks, and is part of a broader clinical program aimed at solid tumors expressing HER2 [9][10]

Shares of Jazz Pharmaceuticals (JAZZ) have gained 11.5% over the past four weeks to close the last trading session at $122.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $177.06 indicates a potential upside of 44.4%.The average comprises 18 short-term price targets ranging from a low of $120 to a high of $230, with a standard deviation of $31.55. While the lowest estimate i ...

Jazz Pharmaceuticals (JAZZ) announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will be marketed under the trade name Ziihera.With this nod, Ziihera gets approved for use in previously treated adult patients with unresectable or metastatic HER2-positive BTC. The approval also makes this drug the first dual HER2-targeted bispecific antibody and chemotherapy-free therapy for treating BTC in th ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-an ...

Investors in Jazz Pharmaceuticals PLC (JAZZ) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $65.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It co ...

Jazz Pharmaceuticals (JAZZ) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Th ...